Research
Modified Citrus Pectin (MCP)
4 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Modified pectin with anticancer activity in breast cancer: A systematic review.
Systematic review of nine articles investigating the anticancer activity of modified pectins (MPs) on breast cancer. Studies included both in vitro and in vivo models, reporting positive results in cell lines and murine models. The review suggests a positive effect of MPs in breast cancer treatment, though further in vivo studies are needed for conclusive evidence.
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.
Prospective phase II study of modified citrus pectin (PectaSol, P-MCP) in 60 patients with non-metastatic biochemically relapsed prostate cancer. After six months, 78% responded to therapy with decreased/stable PSA or improved PSA doubling time, and no grade 3 or 4 toxicity was observed.
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.
Phase II study of PectaSol-Modified citrus pectin (P-MCP) in patients with non-metastatic biochemically relapsed prostate cancer. After 18 months of treatment, 85% of patients had a durable long-term response, with 62% showing decreased/stable PSA and 90% PSADT improvement. No grade 3/4 toxicity was observed.
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Phase II pilot study investigating the effect of modified citrus pectin (Pecta-Sol) on prostate-specific antigen doubling time (PSADT) in 13 men with prostate cancer. PSADT increased in 70% of participants after 12 months of MCP supplementation, suggesting potential benefits for men with recurrent prostate cancer.